Safrosyn S

Safrosyn S

naproxen

Manufacturer:

Pharmaniaga Manufacturing Berhad

Distributor:

Pharmaniaga Logistics
Concise Prescribing Info
Contents
Naproxen Na
Indications/Uses
Musculoskeletal & joint disorders eg, ankylosing spondylitis, OA & RA. Mild to moderate pain eg, dysmenorrhoea. Relief of acute migraine attack. Acute gout.
Dosage/Direction for Use
Musculoskeletal & joint disorders eg, ankylosing spondylitis, OA & RA 275 mg bd or 275 mg in the morning & 550 mg in the evening. Mild to moderate pain eg, dysmenorrhoea 550 mg followed by 275 mg every 6-8 hr. Max dose: 1,375 mg daily. Relief of acute migraine attack 825 mg at 1st attack, then 275 or 550 mg at least ½ hr after initial dose. Max dose: 1,375 mg daily. Acute gout Initially 825 mg followed by 550 mg after 8 hr, then 275 mg 8 hrly.
Administration
Should be taken with food.
Contraindications
Active peptic ulceration.
Special Precautions
History of GI haemorrhage of ulcer, cardiac failure or peptic ulceration, SLE, asthma or bronchospasm, bleeding disorders, CV disease, fluid retention. Renal or hepatic impairment; cirrhosis. Pregnancy & lactation. Childn <16 yr. Elderly.
Adverse Reactions
GI disturbances, headache, dizziness, nervousness, tinnitus, depression, drowsiness, insomnia, hypersensitivity reactions, cystitis, haematuria, acute renal failure, interstitial nephritis, nephritic syndrome, anaemia, thrombocytopenia, neutropenia, eosinophilia, agranulocytosis, LFT abnormalities.
Drug Interactions
Probenecid, lithium, MTX, antihypertensives, diuretics, cyclosporin.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AE02 - naproxen ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
Presentation/Packing
Form
Safrosyn S tab 275 mg
Packing/Price
50 × 10's
Form
Safrosyn S tab 550 mg
Packing/Price
50 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in